GMAB

Genmab AS

$37.00

21.15% · 1Y change

Trend

Strong Bullish

+21.15%

P/E

29.13

Div yield

—

Mkt cap

$22.75B

Beta

0.65

Trend read · Strong Bullish

How GMAB performs — and a starting point for your own research.

Price & mood

Market Mood

PriceEMA 13/73/151 (trend)Range 1Y $23.62 – $40.17

Idea: EMA

1Y Return

+21.4%

Sharpe 3Y

0.99

Market comparison

vs sector & industry

GMAB

1Y performance

+21.15%

Past performance. The future stays open.

Wall Street coverage

third-party context

Wall Street coverage

$44.40median target· current $37.00 (+20.0%)11 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close

P/E ratio29.13Forward 15.08

EPS (TTM)$1.27-9.4% YoY

Profit margin19.1%HEALTHCARE

Market cap$22.75BLarge cap

Valuation

Forward P/E: 15.08
PEG ratio: 4.36
P/B: 3.59
P/S (TTM): 5.51
EV/EBITDA: 19.98

Profitability & growth

ROE (TTM): 14.0%
Operating margin: 35.2%
Revenue growth YoY: 24.9%
Dividend yield: —
Beta: 0.65

Last earnings

Aug 6, 2026 · Estimate $0.37 · Reported $0.54

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Genmab AS

Company profile

Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: CARL JACOBSENS VEJ 30, COPENHAGEN, DENMARK
Fiscal year end: December
Latest quarter: Jun 30, 2026

Market cap$22.75B

Shares outstanding$614.9M

52W high$40.17

52W low$23.62

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

GMAB

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

HC Wainwright raises target for Genmab stock from USD 40 to USD 50

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J

Physician Views Preview: Can AbbVie and Genmab's Epkinly redefine the first-line treatment of DLBCL?

J&J reports $2.53B in U.S. DARZALEX sales. Genmab (GMAB) receives royalties worldwide.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Genmab (GMAB) Receives a Buy from Truist Financial

Genmab (GMAB) Receives a Buy from Truist Financial

Genmab Grants Restricted Stock Units to Board After Extraordinary General Meeting

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab’s Lymphoma Bet Delivers a 51% Knockout

Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug

AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3

European shares gain as Genmab jumps, bond yields retreat By Reuters

AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial

AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy

Fundamentals

Valuation

Profitability & growth

About Genmab AS

Classification

Company profile

GMAB

Price & mood

Market comparison

GMAB Market Analysis

GMAB

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

HC Wainwright raises target for Genmab stock from USD 40 to USD 50

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J

Physician Views Preview: Can AbbVie and Genmab's Epkinly redefine the first-line treatment of DLBCL?

J&J reports $2.53B in U.S. DARZALEX sales. Genmab (GMAB) receives royalties worldwide.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Genmab (GMAB) Receives a Buy from Truist Financial

Genmab (GMAB) Receives a Buy from Truist Financial

Genmab Grants Restricted Stock Units to Board After Extraordinary General Meeting

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab’s Lymphoma Bet Delivers a 51% Knockout

Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug

AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3

European shares gain as Genmab jumps, bond yields retreat By Reuters

AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial

AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy

Fundamentals

Valuation

Profitability & growth

About Genmab AS

Classification

Company profile

GMAB

Price & mood

Market comparison